SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 06/02/2025 at 07:00, 1 year 3 months ago

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease. Acquisition includes Ayvakit/Ayvakyt for systemic mastocytosis and a promising pipeline in immunology

Acquisition Sanofi Rare Diseases Blueprint Medicines Immunological Disease
BRIEF

published on 05/30/2025 at 07:05, 1 year 3 months ago

Itepekimab Reaches Primary Endpoint in COPD Phase 3 Study

Sanofi COPD Regeneron Itepekimab AERIFY-1
PRESS RELEASE

published on 05/30/2025 at 07:00, 1 year 3 months ago

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Itepekimab met primary endpoint in AERIFY-1 study for COPD, with significant reduction in exacerbations. AERIFY-2 did not meet endpoint. Sanofi and Regeneron assessing data for next steps

Sanofi COPD Regeneron Itepekimab AERIFY-1
BRIEF

published on 05/29/2025 at 14:35, 1 year 3 months ago

Positive impact of Beyfortus on hospitalizations due to RSV

Public Health Efficiency Beyfortus VRS Hospitalizations Childhood Vaccination
PRESS RELEASE

published on 05/29/2025 at 14:30, 1 year 3 months ago

Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
Real-world comparison shows Beyfortus and RSVpreF immunization programs reduce infant RSV hospitalizations in Spain and UK. Beyfortus provides sustained protection against RSV with high efficacy and safety profile

RSV Beyfortus RSVpreF Infant Immunization
BRIEF

published on 05/22/2025 at 01:20, 1 year 3 months ago

Sanofi acquires Vigil Neuroscience to strengthen its Alzheimer's research

Acquisition Alzheimer's Disease Sanofi Neurology Vigil Neuroscience
PRESS RELEASE

published on 05/22/2025 at 01:15, 1 year 3 months ago

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
Sanofi acquires Vigil Neuroscience to enhance neurology pipeline with an investigational medicine for Alzheimer's disease. The acquisition includes VG-3927, a small molecule TREM2 agonist

Alzheimer's Disease Sanofi Neurology Vigil Neuroscience VG-3927
BRIEF

published on 05/15/2025 at 19:11, 1 year 3 months ago

Sanofi: Details on Voting Rights and Shares - April 2025

Voting Rights Actions Investment Sanofi April 2025
BRIEF

published on 04/30/2025 at 13:05, 1 year 4 months ago

Sanofi and CD&R finalize the sale of Opella

Sanofi CD&R Assignment Opella Consumer Health
PRESS RELEASE

published on 04/30/2025 at 13:00, 1 year 4 months ago

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creating global consumer healthcare leader. Sanofi's sale of a 50.0% stake to CD&R marks a strategic move with total net cash proceeds of around €10 billion

Transaction Sanofi CD&R Consumer Healthcare Opella

Published on 09/11/2026 at 17:00, 2 hours 26 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 15:25, 4 hours 1 minute ago

Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 4 hours 26 minutes ago

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 4 hours 56 minutes ago

AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 13:58, 5 hours 28 minutes ago

BlackBerry Radar Advances Asset Intelligence for Transportation

View all ACCESSWIRE

Published on 09/11/2026 at 18:15, 1 hour 11 minutes ago

CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:07, 1 hour 19 minutes ago

Holding(s) in Company
Published on 09/11/2026 at 18:06, 1 hour 19 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 09/11/2026 at 17:30, 1 hour 56 minutes ago

NAGRAVISION and Plume Strengthen Connected Home Security for 30 Million Subscribers Worldwide
Published on 09/11/2026 at 17:30, 1 hour 56 minutes ago

Cairn Homes Plc: Holding(s) in Company

View all EQS

Published on 09/11/2026 at 07:00, 12 hours 26 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 12 hours 26 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 23 hours 56 minutes ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 07:00, 1 day 12 hours ago

2026 H1 results and new identity
Published on 09/09/2026 at 18:45, 2 days ago

Successful launch of a €500 million bond issue

View all LES ECHOS COMFI WIRE

News